1. Thomson JA. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145-1147.
2. Chal JJ, Pourquié O. Making muscle: skeletal myogenesis in vivo and in vitro. Development. 2017;144(12):2104-2122. 10.1242/ dev.151035
3. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987;51:987-1000.
4. Constantinides PG, Jones PA, Gevers W. Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature. 1977;267:364-366.
5. Tanaka A, Woltjen K, Miyake K, et al. Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro. PLoS One. 2013;8:e61540.
6. Yasuno T, Osafune K, Sakurai H, et al. Functional analysis of iPSCderived myocytes from a patient with carnitine palmitoyltransferase II deficiency. Biochem Biophys Res Commun. 2014;448:175-181.
7. Shoji E, Sakurai H, Nishino T, et al. Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells. Sci Rep. 2015;5:12831.
8. Gu C, Yang Y, Sompallae R, et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell. 2016;18:533-540.
9. Bitzer M, Armeanu S, Lauer UM, Neubert WJ. Sendai virus vectors as an emerging negative-strand RNA viral vector system. J Gene Med. 2003;5:543-553.
10. Nishimura K, Sano M, Ohtaka M, et al. Development of defective and persistent Sendai virus vector: a unique gene delivery/ expression system ideal for cell reprogramming. J Biol Chem. 2011;286:4760-4771.
11. Ban H, Nishishita N, Fusaki N, et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U. S. A. 2011;108:14234-14239.
12. Goto K, Imamura K, Komatsu K, et al. Simple derivation of spinal motor neurons from ESCs/iPSCs using sendai virus vectors. Mol Ther Methods Clin Dev. 2017;4:115-125.
13. Li H-O, Zhu Y-F, Asakawa M, et al. A Cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol. 2000;74(14):6564-6569.
14. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Japan Acad Ser B Phys Biol Sci. 2009;85(8):348-362. 10.2183/pjab.85.348
15. Kondo T, Imamura K, Funayama M, et al. iPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid β combination for Alzheimer’s disease. Cell Rep. 2017;21:2304-2312.
16. Maffioletti SM, Gerli MFM, Ragazzi M, et al. Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells. Nat Protoc. 2015;10:941-958.
17. Akiyama T, Sato S, Chikazawa-Nohtomi N, et al. Efficient differentiation of human pluripotent stem cells into skeletal muscle cells by combining RNA-based MYOD1-expression and POU5F1-silencing. Sci Rep. 2018;8:1189.
18. Weldon JE, Pastan I. A guide to taming a toxin–Recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 2011;278(23):4683-4700. 10.1111/j.1742-4658.2011.08182.x
19. Tateno H, Onuma Y, Ito Y, et al. Elimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion protein. Stem Cell Rep. 2015;4(5):811-820. 10.1016/j.stemcr.2015.02.016.
20. Tateno H, Saito S, Saito S. Engineering of a potent recombinant lectin-toxin fusion protein to eliminate human pluripotent stem cells. Molecules. 2017;22(7):1151.
21. Juhas M, Engelmayr GC, Fontanella AN, Palmer GM, Bursac N. Biomimetic engineered muscle with capacity for vascular integration and functional maturation in vivo. Proc Natl Acad Sci U S A. 2014;111(15):5508-5513. 10.1073/pnas.1402723111
22. Madden L, Juhas M, Kraus WE, Truskey GA, Bursac N. Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs. Elife. 2015;4:e04885.
23. Kokubu Y, Nagino T, Sasa K, et al. Phenotypic drug screening for dysferlinopathy using patient-derived induced pluripotent stem cells. Stem Cells Transl Med. 2019;8:1017-1029.
24. Fujie Y, Fusaki N, Katayama T, et al. New type of Sendai virus vector provides transgene-free iPS cells derived from chimpanzee blood. PLoS One. 2014;9:e113052.
25. Sugiyama Y, Suzuki A, Kishikawa M, et al. Muscle develops a specific form of small heat shock protein complex composed of MKBP/ HSPB2 and HSPB3 during myogenic differentiation. J Biol Chem. 2000;275:1095-1104.
26. Clerico EM, Tilitsky JM, Meng W, Gierasch LM. How Hsp70 molecular machines interact with their substrates to mediate diverse physiological functions HHS public access. J Mol Biol. 2015;427:1575-1588.
27. Forcales SV, Puri PL. Signaling to the chromatin during skeletal myogenesis: novel targets for pharmacological modulation of gene expression. Semin Cell Dev Biol. 2005;16:596-611.
28. McArdle A, Broome CS, Kayani AC, et al. HSF expression in skeletal muscle during myogenesis: implications for failed regeneration in old mice. Exp Gerontol. 2006;41:497-500.
29. Barone R, Macaluso F, Sangiorgi C, et al. Skeletal muscle Heat shock protein 60 increases after endurance training and induces peroxisome proliferator-activated receptor gamma coactivator 1 α1 expression. Nat. Publ. Gr. 2015;6(1):19781. 10.1038/srep19781